Novartis AG (NVS)

86.99
2.50 2.79
NYSE : Health Technology
Prev Close 89.49
Open 87.65
Day Low/High 86.90 / 87.84
52 Wk Low/High 74.97 / 96.31
Volume 2.52M
Avg Volume 1.86M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 224.37B
EPS 5.50
P/E Ratio 16.66
Div & Yield 1.84 (2.07%)

Latest News

Adding to a Pharmaceutical Name While Taking Gains in a Semi

We will buy more Novartis shares and trim our Lam Research position.

NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM  - NVS

NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM  - NVS

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...

Tech Stocks Lag, Health Care Shakes Up and Apple's in TV

Tuesday is a big day as the rotation in the markets continues -- putting the likes of Salesforce.com on sale; pharma gets jitters over political climate; and Apple aims at Netflix and co.

Two Tuesday Buys

We will add to our Novartis and Twilio positions this morning.

Last Week's Portfolio Changes

We initiated a new position and downgraded another last week.

For Wealth and Safety Invest With a 'Shark'

For Wealth and Safety Invest With a 'Shark'

Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.

ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG - NVS

ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG - NVS

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...

Weekly Roundup

Stocks fell on manufacturing worries, but snapped back by the end of the week on renewed hopes for easing U.S.- China trade tensions.

Recession and Disbelief: Cramer's 'Mad Money' Recap (Thursday 9/5/19)

Recession and Disbelief: Cramer's 'Mad Money' Recap (Thursday 9/5/19)

Jim Cramer says we got good news on trade talks, and strong economic and employment data, all of which add up to a rally that defies recession talk.

Beyond Meat, Yum! Brands, Netflix: 'Mad Money' Lightning Round

Beyond Meat, Yum! Brands, Netflix: 'Mad Money' Lightning Round

Jim Cramer weighs in on Beyond Meat, Yum! Brands, Netflix, Starwood Property Trust, and GW Pharmaceuticals.

Catalyst Events to Watch in Amgen and Novartis Pipelines

The pipeline is key for pharmaceutical companies.

Video: Jim's Daily Rundown for Thursday

Jim discusses his interview with Palo Alto Networks CEO Nikesh Arora, the CVS Health-Aetna merger settlement approval, Goldman Sachs and the Apple card, Novartis and more!

Initiating a Pharmaceutical Name and a Small Retail Trim

We are bringing Novartis out of the bullpen and into the portfolio.

Stocks to Watch on Volatility

A menu of stocks and associated price levels where we think a bit of nibbling and small buying is worth doing.

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Its Investigation On Behalf Of Novartis AG Investors (NVS)

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Its Investigation On Behalf Of Novartis AG Investors (NVS)

Law Offices of Howard G. Smith continues its investigation on behalf of Novartis AG ("Novartis" or the "Company") (NYSE: NVS) investors concerning the Company and its officers' possible violations of federal securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Novartis AG And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Novartis AG And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG ("Novartis" or "the Company") (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities Exchange...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Novartis AG - NVS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Novartis AG - NVS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...

Amgen Declines Following Mizuho Downgrade to Neutral

Amgen Declines Following Mizuho Downgrade to Neutral

Amgen's rating is lowered at Mizuho but its price target gets raised to $212.

Charts of Alcon Look Good

Charts of Alcon Look Good

Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.

Boom or Bust?: Cramer's 'Mad Money' Recap (Thursday 8/15/19)

Boom or Bust?: Cramer's 'Mad Money' Recap (Thursday 8/15/19)

It's not really a boom or a bust, says Jim Cramer. The truth is we're muddling along. But it's hard to outrun the bond bears.

It's Tough to Weed Through the Data on Tilray

It's Tough to Weed Through the Data on Tilray

The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Amgen Climbs After Winning Patent Case on Enbrel

Amgen Climbs After Winning Patent Case on Enbrel

Amgen's patents for Enbrel likely to be protected until 2029.

Novartis (NVS) Alert: Johnson Fistel Launches Investigation Into Novartis AG; Investors Encouraged To Contact Firm

Novartis (NVS) Alert: Johnson Fistel Launches Investigation Into Novartis AG; Investors Encouraged To Contact Firm

SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Novartis AG ("Novartis") (NYSE: NVS) for violations of federal securities laws.

Bullpen Update

These companies already posted strong earnings this season and are not economically sensitive.

FDA Says Some Data From Novartis Gene Therapy Manipulated

FDA Says Some Data From Novartis Gene Therapy Manipulated

The FDA says some data from the testing of Novartis's gene-therapy product Zolgensma was manipulated, but the drug should stay on the market.

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.

TheStreet Quant Rating: A- (Buy)